

Jake R Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3142069/publications.pdf>

Version: 2024-02-01

49
papers

1,201
citations

516710

16
h-index

395702

33
g-index

49
all docs

49
docs citations

49
times ranked

1634
citing authors

#	ARTICLE	IF	CITATIONS
1	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 90-96.	2.8	233
2	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2019, 200, 34-39.	3.2	113
3	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011–2015: A Capture–Recapture Analysis. <i>American Journal of Public Health</i> , 2018, 108, 1675-1681.	2.7	109
4	The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection. <i>Annals of Internal Medicine</i> , 2015, 162, 619-629.	3.9	92
5	Patient Outcomes Following Total Joint Replacement Surgery: A Comparison of Hospitals and Ambulatory Surgery Centers. <i>Journal of Arthroplasty</i> , 2020, 35, 7-11.	3.1	55
6	Economic evaluation of HCV testing approaches in low and middle income countries. <i>BMC Infectious Diseases</i> , 2017, 17, 697.	2.9	43
7	Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2021, 72, 472-478.	5.8	42
8	Predictors of Frequent Emergency Room Visits among a Homeless Population. <i>PLoS ONE</i> , 2015, 10, e0124552.	2.5	39
9	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
10	Antibiotics for Respiratory Tract Infections: A Comparison of Prescribing in an Outpatient Setting. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 153-159.	1.8	36
11	Homelessness, HIV, and Incomplete Viral Suppression. <i>Journal of Health Care for the Poor and Underserved</i> , 2016, 27, 145-156.	0.8	35
12	Will converting naloxone to over-the-counter status increase pharmacy sales?. <i>Health Services Research</i> , 2019, 54, 764-772.	2.0	25
13	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	3.2	25
14	Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. <i>International Journal of Drug Policy</i> , 2019, 72, 160-168.	3.3	23
15	Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs. <i>Drug and Alcohol Dependence</i> , 2018, 185, 411-420.	3.2	22
16	Gynecologic Outcomes After Hysteroscopic and Laparoscopic Sterilization Procedures. <i>Obstetrics and Gynecology</i> , 2016, 128, 843-852.	2.4	20
17	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	5.9	17
18	Characteristics of patients who accept and decline ED rapid HIV testing. <i>American Journal of Emergency Medicine</i> , 2014, 32, 1109-1112.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. <i>Medical Care</i> , 2022, 60, 256-263.	2.4	15
20	Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw266.	0.9	14
21	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1397-1405.	5.8	13
22	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	2.8	13
23	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	3.3	13
24	Using Medical Claims for Policy Effectiveness Surveillance: Reimbursement and Utilization of Abdomen/Pelvis Computed Tomography Scans. <i>Health Services Research</i> , 2015, 50, 1910-1926.	2.0	12
25	Eligibility for cervical cancer screening exit: Comparison of a national and safety net cohort. <i>Gynecologic Oncology</i> , 2021, 162, 308-314.	1.4	11
26	Payments for outpatient joint replacement surgery: A comparison of hospital outpatient departments and ambulatory surgery centers. <i>Health Services Research</i> , 2020, 55, 218-223.	2.0	11
27	Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use. <i>JAMA Network Open</i> , 2022, 5, e2221346.	5.9	10
28	Opioid use disorder and overdose among youth following an initial opioid prescription. <i>Addiction</i> , 2021, 116, 2790-2800.	3.3	9
29	A Qualitative Study of the Real-world Experiences of Infectious Diseases Fellows Regarding Antibiotic Stewardship. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy102.	0.9	8
30	Inappropriate Antibiotic Prescribing for Acute Bronchitis in Children and Impact on Subsequent Episodes of Care and Treatment. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 271-274.	2.0	8
31	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108336.	3.2	8
32	Potential barriers to filling buprenorphine and naltrexone prescriptions among a retrospective cohort of individuals with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2022, 133, 108540.	2.8	8
33	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109190.	3.2	8
34	Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	3.3	8
35	Evaluating Quality of Care for Sexually Transmitted Infections in Different Clinical Settings. <i>Sexually Transmitted Diseases</i> , 2015, 42, 717-724.	1.7	7
36	The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofx267.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2022, 140, 108800.	2.8	7
38	Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 63-65.	1.3	5
39	Implementation of a Nationwide Health Economic Consultation Service to Assist Substance use Researchers: Lessons Learned. <i>Substance Abuse</i> , 2018, 39, 185-189.	2.3	4
40	Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. <i>Journal of Viral Hepatitis</i> , 2022, 29, 474-486.	2.0	3
41	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	3.3	3
42	The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for Hepatitis C (Hep C) Screening Trial: rationale and design of a multi-center pragmatic randomized clinical trial of hepatitis C screening in emergency departments. <i>Trials</i> , 2022, 23, 354.	1.6	3
43	Commentary on Karnik <i>et al</i> .: Harmonization now—the need for consistent, validated measures to identify opioid use disorder in observational data. <i>Addiction</i> , 2022, 117, 2448-2449.	3.3	3
44	Capsule Commentary on Tannenbaum <i>et al.</i> , Nudging Physician Prescription Decisions by Partitioning the Order Set: Results of a Vignette-Based Study. <i>Journal of General Internal Medicine</i> , 2015, 30, 343-343.	2.6	2
45	Getting What You Pay For. <i>Sexually Transmitted Diseases</i> , 2016, 43, 18-22.	1.7	2
46	Obstetric Outcomes After Failed Hysteroscopic and Laparoscopic Sterilization Procedures. <i>Obstetrics and Gynecology</i> , 2018, 131, 253-261.	2.4	2
47	HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients. <i>Advances in Therapy</i> , 2021, 38, 1690-1700.	2.9	2
48	Coal power plant emission exposure and its effect on education access. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2014, 22, 313-321.	1.6	1
49	Gynecologic Outcomes After Hysteroscopic and Laparoscopic Sterilization Procedures. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 82-83.	0.4	0